drugset
Drugs / VK5211
last change Oct 2018 re-read 3 minutes ago

VK5211

also known as LGD-4033 · Ligandrol

Small molecule targets AR

Investigated by
Viking Therapeutics, Inc.

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Filed US (FDA) — acute hip fracture 2015-07-14

“Filed and activated the IND for the clinical development of VK5211, an orally available, non-steroidal SARM for acute hip fracture.” vikingtherapeutics.com ↗

Trials 1

today NCT02578095 · Ph 2
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02578095 Oct 2015 → Nov 2017 — Viking Therapeutics, Inc. Completed Met primary

News releases announcing trial results or a regulatory action · 6

DateIssuerRelease
2018-10-01 Viking Therapeutics, Inc. Results Viking Therapeutics Presents Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture in Plenary Oral Presentation at ASBMR 2018 Annual Meeting vikingtherapeutics.com ↗
2017-11-28 Viking Therapeutics, Inc. Results Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture vikingtherapeutics.com ↗
2016-09-01 Viking Therapeutics, Inc. Results Viking Therapeutics Presents Phase 1 Data and Highlights Ongoing Phase 2 Study of VK5211 at 5th Fragility Fracture Network Global Congress 2016 vikingtherapeutics.com ↗
The results of this study showed VK5211 to be safe, well tolerated, and to have a predictable pharmacokinetic (PK) profile in healthy women and men age 65 and over.
2015-12-07 Viking Therapeutics, Inc. Results Viking Therapeutics Presents New Data on VK5211 Demonstrating Robust Weight Gain in Primates Following 13 Weeks of Treatment vikingtherapeutics.com ↗
Study findings showed robust weight gains in all VK5211 treatment groups as compared to both baseline and controls.
2015-10-20 Viking Therapeutics, Inc. Results Viking Therapeutics Completes Safety, Tolerability and Pharmacokinetic Study of VK5211, a Selective Androgen Receptor Modulator (SARM), in Healthy Elderly Subjects vikingtherapeutics.com ↗
The results of this study showed VK5211 to be safe and well tolerated at all doses evaluated.
2015-07-14 Viking Therapeutics, Inc. Regulatory Viking Therapeutics Submits Investigational New Drug (IND) Application for VK5211, a Selective Androgen Receptor Modulator (SARM), in Acute Hip Fracture vikingtherapeutics.com ↗

All press releases naming this drug 14 releases

DateIssuerRelease

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as VK5211 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02578095 ↗
Known as LGD-4033 ChEMBL registry synonym — accepted as the source's own label CHEMBL5170587 ↗
Known as Ligandrol ChEMBL registry synonym — accepted as the source's own label CHEMBL5170587 ↗
Modality Small molecule — CHEMBL5170587 ↗
Target AR “Androgen Receptor modulator” CHEMBL5170587 ↗